About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy

NCT01695447·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Xue-Li Bai, Ph.D.
CONTACT
+86 571 87783510 shirleybai57@hotmail.com

Lead

TingBo Liang

Age

18–80

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Patients diagnosed with pancreatic cancer or other diseases which need pancreaticoduodenectomy and pancreaticojejunostomy
18 to 80 y/o
Operation-tolerated
Informed consent

You may not be if

History of gastrointestinal operation
Pancreaticoduodenectomy is given up during operation
Pancreatic duct is difficult to locate
Patients require to exit from the study anytime

The record

StatusUnknown

PhaseNo phase

Taking part100

StartedJan 2012

UpdatedJan 26, 2017

Conditions

Pancreatic Neoplasms Biliary Tract Neoplasms

Where1

the Second Affiliated Hospital, School of Medicine, Zhejiang Universtiy
Hangzhou, Zhejiang, China

Clareo Health | Duct-to-mucosa Versus Invagination for Pancreaticojejunostomy